Morning

About Us

At Highland Therapeutics we use proprietary drug-delivery technology to develop improved versions of existing drug products.

Leadership


David Lickrish

President & Chief Executive Officer

David Lickrish is the co-inventor, founding shareholder and Chief Executive Officer of Highland Therapeutics.

Under his leadership, Highland has grown from a start-up company, founded in the midst of the financial crisis, to an international pharmaceutical company with a proprietary drug-delivery technology and two late-stage drugs under development.

Mr. Lickrish studied Microbiology and Finance at the University of Guelph in Canada. He graduated with Honors and received his Bachelor of Commerce in International Economics and Finance. Mr. Lickrish has been a CFA Charter holder since 2001 and has worked internationally covering the Global Pharmaceutical Industry as Senior Vice President of Equity Research.

Nelson Isabel

Chief Financial Officer

Nelson Isabel serves as the Company’s Chief Financial Officer.

Prior to joining Highland, Mr. Isabel spent seven years at Biovail Corporation (now Valeant Pharmaceuticals International, Inc.), Canada’s largest publicly traded pharmaceutical company, where he served on its Finance Leadership Team and was responsible for all investor relations and corporate communication activities. Prior to Biovail, Mr. Isabel was an equity research analyst covering the Canadian healthcare industry with CIBC World Markets and with Desjardins Securities.

Mr. Isabel has a B.Sc. in Experimental Animal Physiology and a Master of Business Administration from the Schulich School of Business in Toronto. He has been a CFA Charter holder since 2002.

Jeff Kent

Senior Vice President, Operations

David Lickrish

President & Chief Executive Officer

David Lickrish is the co-inventor, founding shareholder and Chief Executive Officer of Ironshore Pharmaceuticals & Development, Inc.

Under his leadership, Ironshore has grown from a start-up company, founded in the midst of the financial crisis, to an international pharmaceutical company with a proprietary drug-delivery technology and two late-stage drugs under development.

Mr. Lickrish studied Microbiology and Finance at the University of Guelph in Canada. He graduated with Honors and received his Bachelor of Commerce in International Economics and Finance. Mr. Lickrish has been a CFA Charter holder since 2001 and has worked internationally covering the Global Pharmaceutical Industry as Senior Vice President of Equity Research.

Nelson Isabel

Chief Financial Officer

Nelson Isabel serves as the Company’s Chief Financial Officer.

Prior to joining Ironshore, Mr. Isabel spent seven years at Biovail Corporation (now Valeant Pharmaceuticals International, Inc.), Canada’s largest publicly traded pharmaceutical company, where he served on its Finance Leadership Team and was responsible for all investor relations and corporate communication activities. Prior to Biovail, Mr. Isabel was an equity research analyst covering the Canadian healthcare industry with CIBC World Markets and with Desjardins Securities.

Mr. Isabel has a B.Sc. in Experimental Animal Physiology and a Master of Business Administration from the Schulich School of Business in Toronto. He has been a CFA Charter holder since 2002.

Dr. Bev Incledon

Executive Vice President, Research & Development

Fiona McDougall

Senior Vice President, Operations

Craig Lewis

President, Ironshore Pharmaceuticals America, Inc.

Dr. Randy Sallee

Chief Medical Officer

Tom Curatolo

Executive Vice President,
Commercial Strategy and Operations

Thomas A. Curatolo serves as the Company’s Executive Vice President, Commercial Strategy and Operations.

Prior to joining the Company, Mr. Curatolo spent nine years at Shire Pharmaceuticals. Most recently, he served in the capacity of Vice President, Global Commercial Operations and Commercial Strategy Lead for the Neuroscience Business Unit, which generated $2.2 billion in revenues in 2014. Throughout his career, Mr. Curatolo has been focused on the ADHD market, leading pre-launch, launch and mature product marketing teams for methylphenidate and amphetamine formulations, as well as non-stimulant products, covering the entire spectrum of current ADHD pharmacologic treatment.

Mr. Curatolo has a B.A. in Environmental Economics from Rutgers University and a Master of Business Administration in Marketing Management from St. John’s University.

Don Allen

Senior Vice President, Commercial Manufacturing and Supply

Paul J. Casanova

Senior Vice President Sales

What We Do


Highland Therapeutics Inc. is a Toronto-based pharmaceutical company whose wholly owned subsidiaries are focused on the development and commercialization of novel drugs utilizing the DELEXIS® drug delivery technology platform. DELEXIS® is a proprietary technology developed by Ironshore Pharmaceuticals & Development, Inc. (“Ironshore”), a wholly owned subsidiary of Highland, that allows for the nighttime delivery of medicines, with the object of achieving a therapeutic effect immediately upon wakening and throughout the day.

Ironshore’s lead compound, HLD200 (delayed-release and extended-release methylphenidate), is under development for the treatment of Attention-Deficit/Hyperactivity Disorder, or ADHD. A New Drug Application for HLD200 is currently being reviewed by the U.S. Food and Drug Administration.

HLD100, also under development for the treatment of ADHD, is expected to begin a pivotal Phase 3 trial in H2/2017.

Our Office

Highland Office

Highland Pharmaceuticals

MaRS Centre Heritage Building
101 College St, Suite HL20-2
Toronto, ON Canada M5G 1L7

Ironshore Pharmaceuticals

Ironshore Pharmaceuticals & Development, Inc., a wholly owned subsidiary of Highland Therapeutics Inc., is a pharmaceutical company that is leveraging its proprietary technology, DELEXIS®, to optimize the delivery of previously approved drug products. Visit ironshorepharma.com for more information.

Ironshore Offices

Early Morning Functioning

Ironshore in the United States

US Head Office
1550 Liberty Ridge Dr.
Suite 300
Chesterbrook, PA 19087-5567
United States

Main phone: 484-222-4930

Controlled Release

Ironshore in the Cayman Islands

Research & Development Headquarters
10 Market Street
Suite 715
Camana Bay, KY1-9006
Cayman Islands

Community Support


MaRS Building

Highland Therapeutics Inc. is a client of MaRS Discovery District’s Health Venture Services group, which provides advisory services, connections to talent, customer & capital networks, and market intelligence to high-impact, Ontario-based life sciences ventures, helping them commercialize their ideas and build globally competitive companies.

> Discover MaRS